GRIFULVIN V (griseofulvin, microsize) by Bausch + Lomb is clinical pharmacology griseofulvin absorption from the gastrointestinal tract varies considerably among individuals, mainly because of insolubility of the drug in aqueous media of the upper gi tract. Approved for dermatophyte infections of the skin not adequately treated by topical therapy, hair, nails and 2 more indications. First approved in 1984.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Griseofulvin absorption from the gastrointestinal tract varies considerably among individuals, mainly because of insolubility of the drug in aqueous media of the upper GI tract. Drug absorption has been estimated to range between 27 and 72%. After an oral dose, griseofulvin is…
Worked on GRIFULVIN V at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.